I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Diffuse large B-cell lymphoma (DLBCL) is the most frequent histological type among malignant lymphomas, accounting for approximately 30% of cases.\[[@ref1][@ref2]\] DLBCL is highly chemosensitive and curable. The use of anti-CD20 antibody in addition to chemotherapy has significantly improved outcomes in patients with DLBCL. Rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy has emerged as the standard of care for first-line DLBCL therapy, which can improve long-term survival.\[[@ref3][@ref4]\] However, relapse is detected in approximately 30% of patients despite R-CHOP therapy. Curative effect could be improved. After 6-8 cycles of first-line treatment, non-progressing patients enter in the so called "watch and wait" period in which periodical disease restaging is performed until the progression is reported then a salvage therapy is started, though it\'s got a poor long-term survival. Most patients relapsed within the first 2 or 3 years.\[[@ref5][@ref6]\] Now a new pattern called maintenance therapy refers to the use of systemic therapy, either by continuing the primary drug or switching to a new one, in patients who get objective response or stable disease from the first-line chemotherapy.\[[@ref7][@ref8]\] This was primarily tested in patients with refractory or relapsed (i. e., previously treated) follicular lymphoma, who had a survival benefit with rituximab maintenance therapy \[*HR* for death = 0.58, 95% *CI* (0.42-0.79)\].\[[@ref9][@ref10]\] To date, limited data from randomized clinical trials are available to guide the use of rituximab as maintenance therapy or salvage therapy for DLBCL patients who respond to induction therapy or relapse, and few long-term data have been published. The value of rituximab as maintenance or salvage therapy for DLBCL patients who respond to induction therapy or suffer relapse is yet to be determined.\[[@ref11]\] We performed a systematic review of the literature and a meta-analysis of all randomized trials to evaluate the effects of rituximab maintenance treatment and salvage therapy for patients with DLBCL.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Search strategy {#sec2-1}
---------------

Two independent reviewers performed the literature search, study selection and extraction of data. Any disagreement between the two reviewers was resolved by consensus in meetings that involved all authors. The studies for our meta-analysis were retrieved from searches of the PubMed and Cochrane Library, EMBASE, conference proceedings, databases of ongoing trials, and references of published trials. Search terms included"randomized control trial", "clinical trial","diffuse large B-cell lymphoma" iff "DLBCL","Rituximab" or "monoclonal antibodies", "ituximab" or "monoc" and "salvage therapy", and similar terms were cross-searched. We scanned references of all included trials and reviews identified for additional studies. We included all randomized controlled trials that compared rituximab maintenance therapy and salvage therapy with observation in patients with histologically confirmed DLBCL, regardless of publication status, date of publication, and language.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

For maintenance therapy: the research type was randomized controlled trial; the meta-analysis included patients histologically diagnosed as stage I-IV DLBCL who have reached complete remission (CR)/unconfirmed complete remission (CRu)/partial remission (PR) after induced chemotherapy regardless of chemotherapy regimens, method of administration and dosage.

For salvage therapy: the research type was randomized controlled trials; the meta-analysis included patients histologically diagnosed as stage I-IV DLBCL who have suffered relapse of disease.

We excluded ongoing studies, interim analyses, nonrandomized studies, and studies with 10 or fewer patients per study arm.

Study selection and data extraction {#sec2-3}
-----------------------------------

Two investigators independently screen the titles and abstracts of all studies identified in the literature research to verify compliance with the inclusion and exclusion criteria. When this information was unsatisfactory, we performed a full-text analysis that considered the confined inclusion and exclusion criteria. The third investigator resolved disagreements between two investigators. The reviewers who screened the studies independently performed data extraction and quality assessment of all included articles.

Outcome measures {#sec2-4}
----------------

The primary outcome was overall survival (OS).

Secondary outcomes included progression-free survival (PFS), failure-free survival (FFS), odds ratio (OR) and adverse events.

Data synthesis and statistical analysis {#sec2-5}
---------------------------------------

Studies were grouped on the basis of strategy (maintenance or salvage) and analyzed separately. Further, we compared the pooled effect of the two strategies derived from the two analyses. For time-to-event data, the log hazard ratios (*HR*s) and their variances were estimated using the methods proposed by Parmar *et al*.,\[[@ref12]\] when *CI*s of *HR*s were reported. Otherwise, median survival time, events in each arm, and *P* values of the log-rank or Cox proportional hazard regression model were used to estimate log *HR*s and their variances. The study heterogeneity was tested and *P* \< 0.1 was defined as heterogenous. A fixed-effect model (Mantel-Haenszel) was applied in case of absence of heterogeneity between studies and otherwise a random-effect model was performed. The meta-analysis results were displayed as forest plots. All calculations were performed using Review Manager \[RevMan\], version 5.0 for Windows.

The results were described by forest plots, every square represented each study\'s *OR* or *HR* estimate. The pooled *OR* or *HR* was symbolized by a solid diamond at the bottom of the forest plot and the width of the square represented the 95% *CI* of *OR* or *HR*. The size of the square represents the weight that the corresponding study exerts in the meta-analysis. Potential sources of heterogeneity were explored through stratifying by type of induction therapy (chemotherapy, rituximab, chemotherapy + rituximab), rituximab schedule (one infusion every 2 months; four weekly infusions every 6 months), allocation concealment, blinding, and size of studies. All statistical tests were two-sided.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Description of trials {#sec2-6}
---------------------

We identified 232 potentially relevant trials from our initial electronic search, and excluded 216 trials after a preliminary review. The remaining 16 studies were assessed in detail and 7 randomized controlled trials met the inclusion criteria, three of which involved maintenance therapy and the other four articles involved salvage therapy. All the included trials were published in full text. [Table 1](#T1){ref-type="table"} summarized the baseline characteristics of the participants and the design of the studies included.

###### 

Baseline characteristics for included trials

  Investigators                            No. of patients in meta-analysis   Age (year)   Stage    Quality of allocation concealment   Quality of sequence generation   Treatment status      Rituximab administration protocol           Median follow-up (month)
  ---------------------------------------- ---------------------------------- ------------ -------- ----------------------------------- -------------------------------- --------------------- ------------------------------------------- --------------------------
  Habermann *et al*, 2006^\[[@ref13]\]^    352                                60-92        I-IV     Unclear                             Adequate                         Maintenance therapy   375 mg/m2/w X 4w every 6 mo for 2 y         42
  Haioun *et al*, 2009^\[[@ref14]\]^       269                                18-60        I-IV     Unclear                             Adequate                         Maintenance therapy   375 mg/m2/w X4w                             60
  Jäger *et al*, 2013^\[[@ref15]\]^        440                                \>18         I-IV     Unclear                             Unclear                          Maintenance therapy   375 mg/m2/2w X2 y                           60
  Aviles *et al*, 2010^\[[@ref16]\]^       100                                32-63        III-IV   Unclear                             Adequate                         Salvage therapy       R-ESHAP/ESHAP                               64.5
  Olivieri *et al*, 2006^\[[@ref17]\]^     46                                 18-65        I-IV     Unclear                             Unclear                          Salvage therapy       R-DHAP+HDT+ASCT/DHAP+HDT+ASCT               NA
  Sieniawski *et al*, 2007^\[[@ref18]\]^   38                                 23-62        I-IV     Unclear                             Unclear                          Salvage therapy       R-DHAP+ASCT/DHAP+ASCT                       60
  Vellenga *et al*, 2008^\[[@ref19]\]^     225                                25-65        I-IV     Unclear                             Adequate                         Salvage therapy       R-DHAP-RVIM-RDHAP+ASCT/DHAP-VIM-DHAP+ASCT   31

ID: identity; ASCT: autologous stem cell transplantation; HDT: high-dose chemotherapy; VIM: etoposide-ifosfamide-methotrexate. ; ESHAP:etoposide-methylprednisolone-cytosine-arabinoside-platinum; DHAP: dexamethasone-Cisplatin-Cytarabine

Patient characteristics {#sec2-7}
-----------------------

Three trials included patients with DLBCL who receive rituximab maintenance therapy immediately after induce chemotherapy. One trial\[[@ref13]\] included untreated DLBCL patients 60 years or older who got CR/CRu/PR after R-CHOP or CHOP. One trial\[[@ref14]\] included untreated 18--60 years old patients with CD20 (+) who got CR/CRu/PR after first-line therapy. Two trials\[[@ref14][@ref15]\] made a subgroup analysis according age-adjusted international prognostic index (aaIPI).

Four trials\[[@ref16][@ref17][@ref18][@ref19]\] reported salvage therapy with rituximab on relapse or refractory disease, while one trial\[[@ref16]\] reported patients who received rituximab and normal-dose chemotherapy. Three trials\[[@ref17][@ref18][@ref19]\] reported patients who received rituximab and high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). Other common exclusion criteria of the original trials were poor performance status, active infection, symptomatic central nervous system disease, and a history of serious medical conditions. The follow-up periods ranged from 31 to 64.5 months.

Trial design {#sec2-8}
------------

In three trials,\[[@ref13][@ref14][@ref15]\] patients were randomly assigned to a type of induction therapy and subsequently underwent a second random assignment to maintenance therapy or observation.

In the salvage trials,\[[@ref16][@ref17][@ref18][@ref19]\] all patients were treated with a type of induction therapy and were randomly assigned to salvage therapy or observation after relapse or refractory.

Quality assessment {#sec2-9}
------------------

The quality of included reports was scored using the Jadad composite scale,\[[@ref20]\] which assessed the trials according to the following three questions: (1) whether they reported an appropriate randomization method; (2) whether double blindness was mentioned in the trial and whether the trial was appropriately performed; (3) whether they reported withdrawals and dropouts. The quality scale ranged from 0 to 5 points, with a low-quality report receiving a score of 2 or less and a high-quality report receiving a score of at least 3.

Overall survival {#sec2-10}
----------------

Habermann (2006)\[[@ref13]\] reported patients who were treated with rituximab maintenance therapy had better OS than patients in the observation group \[*HR* = 0.96, 95% *CI* (0.63-1.47), *P* = 0.85\], regardless of R-CHOP or CHOP as induction therapy, but no significant differences were observed. Jäger *et al*.,\[[@ref15]\] reported at a median follow-up of 45 months, in the rituximab maintenance vs. observation groups: three-year OS as 92.0% vs. 90.3% \[*HR* = 0.78 (95% *CI*: 0.49-1.34)\].

Three trials (409 patients) about salvage therapy were eligible for the meta-analysis of OS. No statistical heterogeneity between studies was examined; a random-effect model was used. Patients who were treated with rituximab salvage therapy had statistically significantly better OS than patients in the observation group \[*HR* of death = 0.72, 95% *CI* = 0.55 - 0.94, *P* = 0.02\] \[[Figure 1](#F1){ref-type="fig"}\].

![Pooled *HR*s of OS of patients with refractory or relapsed DLBCL and of control patients. Black squares represent the point estimate, their sizes represent their weight in the pooled analysis, and the horizontal bars represent the 95% *CI*. The black diamond at the bottom represents the pooled point estimate. *HR*: Hazard ratio for death; *CI*: confidence interval; experimental: salvage therapy with rituximab](CMJ-128-378-g001){#F1}

Secondary outcomes EFS PFS OR {#sec2-11}
-----------------------------

Habermann (2006)\[[@ref13]\] reported patients who were treated with rituximab maintenance therapy had statistically significantly better 3-year FFS than patients in the observation group \[*HR* = 0.63, 95% *CI* (0.44-0.90), *P* = 0.009\]. Haioun (2009)\[[@ref14]\] observed an increased 4-year EFS in the rituximab arm compared with the observation arm. In one subgroup analysis, there was a significant improvement in EFS for patients who experienced a CR following ASCT and received maintenance rituximab compared with those who received observation only \[*HR* = 0.38, 95% *CI* (0.19-0.90), *P* = 0.02\]. In another subgroup analysis according to aaIPI, the two groups (aaIPI = 2/aaIPI = 3) all have improvement in EFS, but no statistical significance was observed \[*HR* = 0.66, 95% *CI* (0.27-1.29), *P* = 0.20; *HR* = 0.69, 95% *CI* (0.31-2.01), *P* = 0.70\]. Jäger *et al*.\[[@ref15]\] reported in the rituximab maintenance group vs. observation group, three-year EFS was 80.1% vs. 76.5% \[*HR* = 0.78 (95% *CI*: 0.57-1.08); *P* = 0.067\]; three-year PFS was 86.3% vs. 79.0% \[*HR* = 0.62 (95% *CI*: 0.43-0.90)\]. In the patient subgroups stratified by treatment arm and IPI risk group (≤1 vs. ≥2), EFS was significantly longer in those patients with an IPI risk score ≤ 1 and was longer for rituximab maintenance than observation \[*HR* = 1.67 (95% *CI*: 1.18--2.35); *P* = 0.012\].

Three trials\[[@ref16][@ref17][@ref19]\] (371 patients) about salvage therapy were eligible for the meta-analysis of PFS. Due to no statistical heterogeneity between the studies, a random-effect model was used. The rituximab group has statistically significantly better PFS than the observation group \[*HR* = 0.61, 95% *CI* (0.52-0.72), *P* \< 0.05\] \[[Figure 2](#F2){ref-type="fig"}\].

![Pooled *HR*s of PFS of patients with refractory or relapsed DLBCL and of control patients. Black squares represent the point estimate, their sizes represent their weight in the pooled analysis, and the horizontal bars represent the 95% *CI*. The black diamond at the bottom represents the pooled point estimate. *HR*: Hazard ratio for death; *CI*: confidence interval; experimental: salvage therapy with rituximab.](CMJ-128-378-g002){#F2}

Four trials\[[@ref16][@ref17][@ref18][@ref19]\] (309 patients) about salvage therapy were eligible for the meta-analysis of *OR*. There is no statistical heterogeneity between studies; a random-effect model was used. The rituximab group has statistically significantly better *OR* than the observation group \[*RR* = 1.26, 95% *CI* (1.07-1.47), *P* = 0.004\] \[[Figure 3](#F3){ref-type="fig"}\].

![Pooled *OR* of patients with refractory or relapsed DLBCL and of control patients. Black squares represent the point estimate, their sizes represent their weight in the pooled analysis, and the horizontal bars represent the 95% *CI*. The black diamond at the bottom represents the pooled point estimate. *OR* : overall remission rate; *CI*: confidence interval; experimental: salvage therapy with rituximab](CMJ-128-378-g003){#F3}

Adverse events {#sec2-12}
--------------

The main adverse events were Grade 3 or 4 leukocytopenia and infection, which were reported in three trials.\[[@ref15][@ref16][@ref18]\] Specifically, patients who underwent rituximab as second-line therapy had more infection-related adverse events than patients in the observation arm \[*RR* = 1.37, 95% *CI* = (1.14 - 1.65) *P* \< 0.05\] \[[Figure 4](#F4){ref-type="fig"}\].

![Infection-related adverse events in patients with DLBCL treated with rituximab compared with observation. Black squares represent the point estimate, their sizes represent their weight in the pooled analysis, and the horizontal bars represent the 95% *CI*. The black diamond at the bottom represents the pooled point estimate. *CI*: confidence interval; experimental: salvagetherapy with rituximab](CMJ-128-378-g004){#F4}

In first-line treatment of DLBCL, the addition of the monoclonal antibody rituximab to standard chemotherapy has consistently been shown to improve results with regard to overall remission rates, PFS and OS.\[[@ref21]\]

In contrast, to date a few prospective randomized trials exist to determine the value of adding rituximab to maintenance therapy or salvage chemotherapy after first-line treatment for relapsed or refractory DLBCL. To our knowledge, there is no published meta-analysis about this question.

In this meta-analysis seven studies were included, three of which were about rituximab maintenance therapy. Due to the heterogeneity between studies, we made a systematic review which demonstrated that rituximab maintenance treatment improved OS and FFS after induction chemotherapy regardless of whether conventional chemotherapy or immuno-chemotherapy was chosen in induction therapy, but there was no statistical significance observed about OS, despite this effect on FFS was statistically significant, especially for the subgroup patients whose induction chemotherapy did not contain rituximab. Maintenance treatment after high-dose chemotherapy followed by ASCT in first-line treatment with rituximab prolonged EFS in either aaIPI 2 or 3 and CRu/PR subgroup, but there was no statistical significance, except for CR subgroup. So whether rituximab maintenance is a good option after first-line chemotherapy needs more prospective, randomized controlled study to provide evidence.

We didn't observed significant heterogeneity among studies in the analysis of rituximab salvage therapy, so we made a meta-analysis, which demonstrated that rituximab combining high-dose chemotherapy and ASCT salvage therapy statistically significant improved OS, PFS, *OR* and disease control compared with observation in patients with refractory or relapsed DLBCL who responded to induction therapy. Despite different kinds of induction therapy and salvage chemotherapy regimens, this meta-analysis showed that rituximab-combined salvage therapy improved OS, PFS, *OR* than conventional high-dose chemotherapy with ASCT; the differences were statistically significant.

Three studies reported the adverse events. The most common adverse events were infections. We all know that rituximab may cause immunosuppression through several mechanisms, such as neutropenia and hypogammaglobulinemia.\[[@ref22][@ref23]\] These effects might be of even greater clinical significance when rituximab is administered in maintenance or salvage therapy.\[[@ref24]\] Meantime, the financial costs of this rituximab should be taken into consideration.

This study has several other limitations. Heterogeneity is a potential problem that affects the results. Many factors might cause significant heterogeneity, such as different induction therapy, second-line treatment regimens, rituximab administration protocols, aaIPI and ASCT. Furthermore, due to very few studies, low methodological quality assessment and low outcome evidence quality, it\'s not confirmed that rituximab-combined salvage therapy is better than normal chemotherapy regimens. More high-quality randomized controlled trials are needed to provide reliable evidence.

Rituximab maintenance as a new strategy is rising in the treatment of DLBCL after first-line therapy. However, to date there is still lack of trials comparing the strategy of rituximab maintenance therapy to rituximab second-line treatment. So for DLBCL, the doubt persists whether to give rituximab maintenance directly when first-line therapy ends or to follow "watch and wait" procedure until disease progression. It needs more prospective, randomized controlled study to provide the evidence.
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